Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
Kai Rejeski, Specialist in Internal Medicine and Hematology and Oncology at LMU Klinikum München, shared a post on X about a recent article he and his colleagues co-authored, adding:
”Not all CHIP is created equal when it comes to CAR-T…TP53 mutant CHIP stands out:
- more cytopenias, higher baseline CAR hematotox, reduced CAR expansion and inferior outcomes
- distinct inflamm. proteomic signature”
Title: TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy
Authors: Giulia Rappa, Frank Ziemann, Kieron White, Linus Kruk, Samar Shamas, Amelie Muth, Kayleen Shi, Cristina Zucchinetti, Savanna Süß, Maja Rothenberg-Thurley, Alessandra Holzem, Tobias Tix, Agnese Petrera, Bianka Ksienzyk, Charlotte Bentenrieder, Katharina S. Götze, Fabian Müller, Veit Bücklein, Kai Rejeski, Marion Subklewe
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 26, 2026, 17:09Kemal Karaagac: NOACs May Offer Cognitive and Clinical Benefits in AF With Alzheimer’s Disease
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal